Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference
Retrieved on:
Wednesday, October 20, 2021
Spiez Laboratory, Clinical trial, World, DARPin, NASDAQ, Molecular Partners, Death, Risk, WHO, Form, RSV, Twitter, Private Securities Litigation Reform Act, COVID-19, Ophthalmology, Humanitarian use licenses, Part, Incidence, Treatment, Molecule, Security (finance), SPR, University Hospital Center Dr Dragiša Mišović, ACTIV, Surface plasmon resonance, Severe acute respiratory syndrome coronavirus 2, Infection, Complementarity, World Health Organization, International Society, U.S. Securities and Exchange Commission, Investor, NIH, Vaccination, Viral load, Company, GLOBE, Patient, University, RBD, Population, SEC, Novartis, Marketing, Therapy, ACE2, University of Lausanne, Pharmaceutical industry, Vaccine
In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.
Key Points:
- In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.
- As such, we must continually test ensovibep against new variants to ensure it has the potential to still be relevant for current and future patients.
- Finally, viral passaging experiments show ensovibep as comparable to monoclonal antibody cocktails with respect to minimizing the development of escape mutants.
- Molecular Partners and Novartis are collaborating on the development of ensovibep and are evaluating it in global late-stage study.